Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

富马酸喹硫平缓释片 - NMPA Drug Approval Details

Approvals/NMPA/Quetiapine Fumarate Extended-Release Tablets

Approved

化学药品

Quetiapine Fumarate Extended-Release Tablets

PHARMATHEN INVESTMENTS GROUP LIMITED🇨🇳 National Medical Products Administration

Approval Date: Jul 12, 2021
Approval ID: 8DqleGdAFUN
Company: PHARMATHEN INVESTMENTS GROUP LIMITED
Type: 化学药品

Approval Details

Approval Id: 8DqleGdAFUN
Approval Number: 国药准字HJ20210055
Generic Name: 富马酸喹硫平缓释片
Generic Name En: Quetiapine Fumarate Extended-Release Tablets
Drug Type: 化学药品
Dosage Form: 片剂
Strength: 50mg(按C21H25N3O2S计)
Reg Date: 2021-07-12
Expired Date: 2026-07-11
Company Name: PHARMATHEN INVESTMENTS GROUP LIMITED
Production Company Name: PHARMATHEN INTERNATIONAL S.A.
Company Detail Path: /organization/pharmathen-investments-group-limited
Production Company Detail Path: /organization/pharmathen-international-s-a

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Jul 12, 2021

Approval ID

8DqleGdAFUN

Type

化学药品

Back to NMPA Approvals